Izofluran

When ATH:
N01AB06

Characteristic.

Transparent, Colorless, stable, non-flammable liquids, containing no additives or chemical stabilizers with moderately spicy, musty smell of ether, destroyed by prolonged standing in the light. Not destroyed by carbon dioxide, aluminum, gland, Copper, tin and bronze.

Pharmacological action.
Inhalation anesthetic.

Application.

Inhalation anesthesia.

Contraindications.

Hypersensitivity, genetic susceptibility to malignant hyperthermia.

Side effects.

In the induction phase: cough, difficulty breathing, laringospazm; in the phase of anesthesia - respiratory depression, gipotenziya, arrhythmias; postoperative - light fever, nausea, vomiting, ileus, abnormal liver function, intellectual and mental disorders (2-3 Days after anesthesia), worsening of mood (during 6 days), leukocytosis, transient increase in blood glucose, creatinine, BUN, cholesterol and alkaline phosphatase, malignant hyperthermia syndrome, giperkatabolicheskimi related processes in skeletal muscle and a sharp increase in oxygen consumption, manifested by muscle rigidity, taxikardiej, increased frequency of respiratory movements, cyanosis, arrhythmias, unstable blood pressure; decrease in the partial pressure of oxygen and the pH, hyperkalemia, alkalipenia; renal failure.

Cooperation.

The combination of nitrous oxide reduces 2-3 times the minimum required for anesthesia alveolar concentration, and it reduces the severity of arterial hypotension. Potentiates the effect of muscle relaxants, especially non-depolarizing type.

Dosing and Administration.

Inhalation, using anesthetic vaporizer. Use inhalation of 1.5-3% isoflurane in oxygen or mixtures of oxygen and nitrous oxide, surgical level of anesthesia is achieved in 7-10 minutes. It can support the inhalation of 1.0-2.5% isoflurane in combination with nitrous oxide; If you use pure oxygen, may require increased concentration of 0.5-1%.

Precautions.

It is used only under the supervision of an anesthesiologist. As sedation is preferable to use anticholinergic drugs. Side effects, resulting in the induction phase, can be reduced by assigning the hypnotic doses of barbiturates ultrakorotkodeystvuyuschih. Careful monitoring of respiratory function. In patients with coronary artery disease to maintain normal hemodynamic parameters it is particularly important for the prevention of myocardial ischemia. A transient increase in cerebrospinal fluid pressure in the deeper stages of anesthesia hyperventilation is corrected. Use of isoflurane anesthesia for abortion can be accompanied by increased blood loss.

Cooperation